TCW Group Inc. Buys 3,300 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

TCW Group Inc. boosted its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 2.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 123,400 shares of the company’s stock after purchasing an additional 3,300 shares during the period. TCW Group Inc.’s holdings in Fulgent Genetics were worth $2,279,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in FLGT. GAMMA Investing LLC boosted its stake in shares of Fulgent Genetics by 45.5% during the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company’s stock worth $39,000 after acquiring an additional 667 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Fulgent Genetics during the 3rd quarter worth $46,000. R Squared Ltd purchased a new position in shares of Fulgent Genetics during the 4th quarter worth $74,000. Gladius Capital Management LP purchased a new position in shares of Fulgent Genetics during the 3rd quarter worth $81,000. Finally, Easterly Investment Partners LLC purchased a new position in shares of Fulgent Genetics during the 3rd quarter worth $208,000. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

FLGT opened at $16.75 on Tuesday. Fulgent Genetics, Inc. has a fifty-two week low of $15.99 and a fifty-two week high of $25.50. The firm’s fifty day moving average is $17.61 and its 200 day moving average is $19.71. The stock has a market cap of $512.33 million, a price-to-earnings ratio of -3.03 and a beta of 1.39.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on FLGT shares. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Piper Sandler lowered their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.